Gain Therapeutics, Inc. Common Stock (GANX)
Gain Therapeutics, Inc. (GANX) is a biotechnology company focused on developing innovative treatments for rare and underserved diseases. Utilizing its proprietary allosteric modulation platform, the company aims to discover and develop therapeutics that target enzymes and other proteins involved in disease pathways. Gain Therapeutics emphasizes precision medicine approaches to address unmet medical needs.
Company News
Gain Therapeutics will participate in the 2025 Maxim Growth Summit, with CEO Gene Mack joining a panel discussion on neurodegenerative diseases and presenting their lead drug candidate GT-02287 for Parkinson's disease treatment.
Several healthcare stocks saw significant price movements in Thursday's pre-market session, with notable gainers including Autonomix Medical, Inspire Veterinary, and Salarius Pharmaceuticals, while Gain Therapeutics, Senti Biosciences, and Aspira Womens Health declined.
Adherex Technologies (FENC) delivered earnings and revenue surprises of -16.33% and 142.70%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?